Ginkgo Bioworks Holdings, Inc.
DNANYSEHealthcare● Active
$8.09
$-0.13(-1.58%)
Market Cap$528475173
P/E Ratio—
52W High$17.58
52W Low$5.37
Ginkgo Bioworks Holdings, Inc.（DNA）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · DNA · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.31B) | ($0.55B) | ($0.89B) | ($2.11B) | ($1.84B) |
| Depreciation & Amort. | $0.06B | $0.06B | $0.07B | $0.04B | $0.03B |
| Stock-Based Comp. | $0.08B | $0.11B | $0.23B | $1.93B | $1.61B |
| Change in Working Capital | ($0.04B) | ($0.09B) | $0.03B | ($0.04B) | ($0.06B) |
| Net Cash from Operations | ($0.17B) | ($0.32B) | ($0.30B) | ($0.25B) | ($0.25B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.01B) | ($0.06B) | ($0.04B) | ($0.05B) | ($0.06B) |
| Purchases of Investments | ($0.42B) | $0.00B | $0.00B | ($0.00B) | ($0.01B) |
| Sales of Investments | $0.19B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.24B) | ($0.06B) | ($0.08B) | ($0.07B) | ($0.07B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | ($0.00B) | $0.00B | ($0.02B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Cash from Financing | $0.02B | ($0.00B) | ($0.00B) | $0.10B | $1.53B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.18B) | ($0.38B) | ($0.34B) | ($0.30B) | ($0.31B) |
| FCF Margin %(computed) | -105.04% | -168.31% | -133.74% | -63.74% | -98.89% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Ginkgo Bioworks Holdings, Inc.
关于Ginkgo Bioworks Holdings, Inc.（DNA）现金流量表
Ginkgo Bioworks Holdings, Inc. 2025财年经营活动现金流($0.17B)，自由现金流($0.18B)（FCF利润率-105.04%），资本支出($0.01B)。
常见问题
DNA · 4 问Ginkgo Bioworks Holdings, Inc. 2025财年自由现金流($0.18B)，同比up53.2%。
DNA free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10